Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulmozyme in Ischemic Stroke (NETs-target)
NCT04785066Phase 2Completed
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Aug 2022
- Primary completion
- Aug 2025
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of dornase alfa in ischemic stroke, sponsored by Adolphe de Rothschild Foundation Hospital. Started Aug 2022; status: completed.
02
Drugs
dornase alfa
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04785066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04785066.